74/100 B+ · Elevated risk
No major risk flags in public sources TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.

✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)

EYE TECH CARE

Active Public limited company (SA) Scientific research & development Active for 17 years

Public limited company (SA) · RC 505187526 · Active since 2008

B+

Overview

EYE TECH CARE is a public limited company (sa) registered in France, since 2008. The company operates in the scientific research & development sector. With reported revenue of 625K EUR in 2015. Its TraceComp score of 74 (B+) indicates moderate risk with some areas to watch. With 17 years of operations, the company has an established track record in its market.

Company Information

Registration Number
505187526
Legal Form
Public limited company (SA)
Registered
2008-07-08

Financial Profile

Latest filed accounts: FY 2015 · most recent available in public filings

Revenue (2015) 625,387 EUR
Net Income -3,363,805 EUR
Total Assets 14,603,337 EUR
Altman Z 0.27 distress

Multi-year financials & ratios

1 year of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

9 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
BERNARD JACQUES ALEXANDRE GILLY Officer Current
+ 8 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Public Contracts Won

Awarded 4 public-sector contracts totalling EUR 149,645 (DECP).

Which public buyers, contract titles, values and award dates.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 17 publications · 942 citations · h-index 18 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (91%) · Engineering (6%) · Biochemistry, Genetics and Molecular Biology (3%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 9 patents · 9 active · 9 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Net loss reported in FY 2015
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.